The abstract is read at the publisher; the summary is JClub's.
Zenocutuzumab produced an investigator-assessed overall response rate of 36.8% (95% CI 16.3–61.6) in 19 advanced NRG1+ cholangiocarcinoma patients.
- Why it matters: Targeted options are lacking for neuregulin 1 gene fusion-positive cholangiocarcinoma, despite zenocutuzumab being approved for other NRG1+ cancers.
- What they did: In the single-arm eNRGy phase II trial, 22 adults received zenocutuzumab 750 mg IV every 2 weeks; efficacy used RECIST v1.1 ORR, with DOR, CBR, PFS, and safety tracked.
- The result: Responses were durable (median DOR 7.4 months; median time to response 1.9 months) with CBR 57.9% and median PFS 9.2 months, while most TRAEs were grade 1–2 and no patients stopped due to an AE.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.